---
title: "MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295126624.md"
description: "MiNK Therapeutics reported early Phase 2 data for agenT-797 in severe hypoxemic pneumonia. Day 28 observations showed improved breathing support, stable circulation, better infection control, and reduced inflammation with no major serious adverse events. Enrollment continues in Lviv with U.S. sites opening; additional data is expected in early 2027."
datetime: "2026-08-06T16:01:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295126624.md)
  - [en](https://longbridge.com/en/news/295126624.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295126624.md)
generator: "portal-rs"
---

# MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trial

-   Mink Therapeutics presented early Day 28 observations from an ongoing randomized Phase 2 trial of agenT-797 in severe hypoxemic pneumonia. \* First treated patients were alive at the endpoint, with clinical signs consistent with improved breathing support needs and more stable circulation. \* Lab analyses from blood and lung fluid suggested better infection control, lower inflammation, immune recovery, tissue repair, and pulmonary recovery. \* No major serious adverse events were attributed to agenT-797 in the initial patients. \* Enrollment continues in Lviv; U.S. sites are opening; additional data are expected in early 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INKT.US](https://longbridge.com/en/quote/INKT.US.md)

## Related News & Research

- [MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial Advances](https://longbridge.com/en/news/295902568.md)
- [Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS](https://longbridge.com/en/news/296776352.md)
- [Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 | AVLN Stock News](https://longbridge.com/en/news/296823873.md)
- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [Vivos Opens New Henderson Sleep Testing and Treatment Center](https://longbridge.com/en/news/296656579.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**